FDA will issue formal guidance requiring mandatory cardiac screening protocols (ECG, QTc thresholds) for any ibogaine IND by Q3 2026, effectively gatekeeping clinical access without blocking analog development.

The FDA (the US drug regulator) will publish official rules saying anyone testing ibogaine in humans must do EKG heart tests first and check for dangerous heart rhythms. This matters because ibogaine can affect your heart, and regulators need to protect trial volunteers—but the new rules won't stop companies from developing safer versions of ibogaine.

Multiple ibogaine cardiac safety papers constitute a regulatory forcing function FDA cannot ignore without institutional liability. Formal guidance is the minimally invasive, institutionally predictable response. However, FDA guidance timelines routinely slip; Q3 2026 is aggressive given FDA's current bandwidth and the agency's preference for advisory committee input before formal guidance. Confidence trimmed slightly to reflect timeline risk.